Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ. 2012. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. [Online]. Figshare Digital Repository. Available from: https://doi.org/10.17037/DATA.24.
Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. [Internet] LSHTM Data Compass. Figshare Digital Repository; 2012. Available from: https://doi.org/10.17037/DATA.24.
Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ (2012). Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. [Data Collection]. Figshare Digital Repository. https://doi.org/10.17037/DATA.24.
Description
Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection in a pre-specified primary endpoint of a Phase IIa/b clinical trial designed to assess vaccine efficacy. Cell-mediated responses, acting in conjunction with functional antibodies, may be necessary for immunity against blood-stage P. falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question.
Data capture method | Experiment: Laboratory |
---|---|
Date (Published in a 3rd party system) | 21 February 2012 |
Language(s) of written materials | English |
Data Creators | Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ |
---|---|
LSHTM Faculty/Department | Faculty of Infectious and Tropical Diseases > Dept of Clinical Research |
Participating Institutions | London School of Hygiene & Tropical Medicine |
Depositor | Gareth Knight |
---|---|
Date Deposited | 23 Nov 2015 13:15 |
Last Modified | 18 Jan 2019 00:50 |
Publisher | Figshare Digital Repository |